Literature DB >> 27791519

Safety and efficacy of the Pipeline embolization device for treatment of intracranial aneurysms: a pooled analysis of 3 large studies.

David F Kallmes1, Waleed Brinjikji1, Saruhan Cekirge2, David Fiorella3, Ricardo A Hanel4, Pascal Jabbour5, Demetrius Lopes6, Pedro Lylyk7, Cameron G McDougall8, Adnan Siddiqui9.   

Abstract

OBJECTIVE The authors performed a pooled analysis of 3 studies-IntrePED (International Retrospective Study of the Pipeline Embolization Device), PUFS (Pipeline for Uncoilable or Failed Aneurysms Study), and ASPIRe (Aneurysm Study of Pipeline in an Observational Registry)-in order to assess angiographic outcomes and clinical safety of the Pipeline embolization device (PED). METHODS IntrePED was a retrospective study, while PUFS and ASPIRe were prospective studies. For each patient included in these studies, the authors collected baseline demographic data, aneurysm characteristics, and procedural details. The primary outcomes for this combined analysis were clinical outcomes, including neurological morbidity and mortality and major ipsilateral intracranial hemorrhage and ischemic stroke. The secondary outcomes were angiographic occlusion rates, which were available for ASPIRe and PUFS only. RESULTS A total of 1092 patients with 1221 aneurysms were included across the 3 studies. The mean aneurysm size was 12.0 ± 7.8 mm and the mean neck size was 6.6 ± 4.8 mm. The major ipsilateral ischemic stroke rate was 3.7% (40/1091). The major ipsilateral intracranial hemorrhage rate was 2.0% (22/1091). The major neurological morbidity rate was 5.7% (62/1091). The neurological mortality rate was 3.3% (36/1091). The combined major morbidity and neurological mortality rate was 7.1% (78/1091). The complete occlusion rates were 75.0% at 180 days (111/148) and 85.5% at 1 year (94/110). The overall aneurysm retreatment rate was 3.0% (33/1091) at a mean follow-up time of 10.2 ± 10.8 months. CONCLUSIONS Endovascular treatment of intracranial aneurysms with the PED is safe and effective. Angiographic occlusion rates progressed with follow-up. Rates of stroke, hemorrhage, morbidity and mortality, and retreatment were low, especially given the fact that the aneurysms treated were generally large and wide necked.

Entities:  

Keywords:  ASPIRe = Aneurysm Study of Pipeline in an Observational Registry; ICA = internal carotid artery; IQR = interquartile range; IntrePED = International Retrospective Study of the Pipeline Embolization Device; PED = Pipeline embolization device; PUFS = Pipeline for Uncoilable or Failed Aneurysms Study; aneurysm; endovascular; interventional neurosurgery; stroke; vascular disorders

Mesh:

Year:  2016        PMID: 27791519     DOI: 10.3171/2016.8.JNS16467

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  46 in total

1.  Apologia of transparency: answer to the letter of L. Pierot.

Authors:  René Chapot; Aglae Velasco González
Journal:  Neuroradiology       Date:  2019-02-28       Impact factor: 2.804

2.  Wide-neck aneurysms: which technique should we use?

Authors:  Laurent Pierot
Journal:  Neuroradiology       Date:  2019-01-06       Impact factor: 2.804

3.  A comparative study of transradial versus transfemoral approach for flow diversion.

Authors:  Joshua H Weinberg; Ahmad Sweid; Batoul Hammoud; Ashlee Asada; Cannon Greco-Hiranaka; Keenan Piper; Michael Reid Gooch; Stavropoula Tjoumakaris; Nabeel Herial; David Hasan; Hekmat Zarzour; Robert H Rosenwasser; Pascal Jabbour
Journal:  Neuroradiology       Date:  2021-02-09       Impact factor: 2.804

4.  Aneurysm Remnants after Flow Diversion: Clinical and Angiographic Outcomes.

Authors:  T P Madaelil; J A Grossberg; B M Howard; C M Cawley; J Dion; R G Nogueira; D C Haussen; F C Tong
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

5.  Outcome prediction of intracranial aneurysm treatment by flow diverters using machine learning.

Authors:  Nikhil Paliwal; Prakhar Jaiswal; Vincent M Tutino; Hussain Shallwani; Jason M Davies; Adnan H Siddiqui; Rahul Rai; Hui Meng
Journal:  Neurosurg Focus       Date:  2018-11-01       Impact factor: 4.047

6.  Recurrence of a totally occluded aneurysm after treatment with a pipeline embolization device.

Authors:  Felipe Padovani Trivelato; Alexandre Cordeiro Ulhôa; Marco Tulio Rezende; Luis Henrique Castro-Afonso; Daniel Giansante Abud
Journal:  BMJ Case Rep       Date:  2018-04-25

7.  Clinical and angiographic outcomes in patients with intracranial aneurysms treated with the pipeline embolization device: intra-procedural technical difficulties, major morbidity, and neurological mortality decrease significantly with increased operator experience in device deployment and patient management.

Authors:  Josser E Delgado Almandoz; Yasha Kayan; Andrea Tenreiro; Adam N Wallace; Jill M Scholz; Jennifer L Fease; Anna M Milner; Maximilian Mulder; Kyle M Uittenbogaard; Oscar Tenreiro-Picón
Journal:  Neuroradiology       Date:  2017-10-06       Impact factor: 2.804

8.  In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials.

Authors:  Ali Sarrami-Foroushani; Toni Lassila; Michael MacRaild; Joshua Asquith; Kit C B Roes; James V Byrne; Alejandro F Frangi
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 14.919

9.  Hemodynamic Analysis of Postoperative Rupture of Unruptured Intracranial Aneurysms after Placement of Flow-Diverting Stents: A Matched Case-Control Study.

Authors:  W Li; Z Tian; W Zhu; Y S Zhang; K Wang; Y Zhang; Y Wang; X Yang; J Liu
Journal:  AJNR Am J Neuroradiol       Date:  2019-10-17       Impact factor: 3.825

10.  Neck Location on the Outer Convexity is a Predictor of Incomplete Occlusion in Treatment with the Pipeline Embolization Device: Clinical and Angiographic Outcomes.

Authors:  T Sunohara; H Imamura; M Goto; R Fukumitsu; S Matsumoto; N Fukui; Y Oomura; T Akiyama; T Fukuda; K Go; S Kajiura; M Shigeyasu; K Asakura; R Horii; C Sakai; N Sakai
Journal:  AJNR Am J Neuroradiol       Date:  2020-11-12       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.